4/A: Pasithea Therapeutics Director Corrects Stock Option Exercise Price in Amended SEC Filing
SEC Filing (Form 4/A)
Simon Dumesnil, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.
Summary
- Simon Dumesnil, a director of Pasithea Therapeutics Corp., filed an amended Form 4/A with the SEC.
- The purpose of the amendment is to correct the exercise price of a stock option previously reported as $8.34 per share.
- The correct exercise price is $8.13 per share, based on the closing price of Pasithea Therapeutics' common stock on March 1, 2024.
- The stock option was granted on March 1, 2024, for 7,500 shares of common stock and expires on February 28, 2034.
- The option vests at a rate of 33% on each one-year anniversary of the grant date, contingent on the reporting person remaining a director.
- A 1-for-20 reverse stock split was effected by the Issuer on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in filings is generally viewed favorably.
Industry Context
This filing is a routine disclosure related to stock options and insider transactions, common in publicly traded companies. The correction of the exercise price suggests attention to detail in regulatory filings.
Stakeholder Impact
- Shareholders may appreciate the correction of information, ensuring transparency.
Key Dates
| Date | Description |
|---|---|
| 2024-01-02 | Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20 |
| 2024-03-01 | Date of stock option grant and earliest transaction date; exercise price corrected to $8.13 per share. |
| 2024-04-05 | Date of Form 4/A filing. |
| 2034-02-28 | Expiration date of the stock option. |
Keywords
Form 4/A, Pasithea Therapeutics, Stock Option, Director, SEC Filing, KTTA, Dumesnil, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.